Abbott International LLC

Annual Accounts
For the Year Ended 30 November 2008

Registered number: FC21622

WEDNESDAY

A38

30/12/2009 COMPANIES HOUSE 90

Profit and Loss Account For the years ended 30 November 2007 and 2008

	Note	2008 \$'000	2007 \$'000
Operating Profit		3,868	668,122
Interest Income (net)		0	0
Profit on ordinary activities before taxation		3,868	668,122
Tax on profit on ordinary activities	4	(3,701)	(237,923)
Profit on ordinary activities after taxation		167	430,199
Dividends Paid	5	0	0
	13	167	430,199

All the operations of the company continued throughout the year and no material operations were acquired or discontinued.

There are no recognized gains or losses in either year other that the (loss)/profit for that year.

The accompanying notes are an integral part of this profit and loss account.

Balance Sheet As of 30 November 2007 and 2008

	Note	2008 \$'000	2007 \$'000
Fixed Assets			
Tangible Assets	6	24,552	14,804
Investments	7	8,975	8,975
Total Fixed Assets		33,527	23,779
Current Assets			
Stocks / Inventories	8	37,260	38,013
Debtors .			
-Due within one year	9	816,896	1,020,775
-Due after one year	9	3,288	7,620
Cash at Bank and in hand		73	82
Total Current Assets		857,516	1,066,490
Total Assets		891,043	1,090,269
Creditors: Amounts falling due within one year	10	(121,560)	(307,160)
Net Current Assets		769,483	783,109
Deferred Income		0	0
Net Assets		769,483	783,109
Capital and Reserves			
Called-up share capital		53,424	53,424
Profit and loss account			
Shareholders' funds		53,424	53,424

The accompanying notes are an integral part of this profit and loss account.

3 Abbott International LLC

Notes to Accounts

1 Statement of accounting policies

The principal accounting policy are summarised below. They have all been applied consistently throughout the year and the preceding year.

Basis of accounting

The accounts have been prepared under the historical cost convention and in accordance with applicable accounting standards.

The company has taken advantage of the exemption under FRS 1 not to prepare a Cash Flow Statement as it is a wholly owned undertaking of Abbott Laboratories whose consolidated accounts are publicly available.

Tangible fixed assets

Tangible fixed assets are stated at cost, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets on a straight-line basis over its expected useful life, as follows:

Leasehold Improvements

10 - 15 years

Plant and machinery

3 - 10 years

Stocks

Stocks are stated at cost. Provision is made for obsolete, slow-moving or defective items where appropriate.

Pension Cost

The company is a member of the Abbott pension fund that provides a defined benefit pension for all permanent employees under which contributions by employees and the company are held by a separately administered trustee company. Actuarial valuations are carried out at two-year intervals.

The amount charged to the profit and loss account in respect of pension costs and other post-retirement benefit is the estimated regular cost of providing the benefits accrued in the year, adjusted to reflect variations from that cost. The regular cost is calculated so that it represents a substantially level percentage of current and future payroll. Variations from regular costs are charged or credited to profit and loss account as a constant percentage of payroll over the estimated average remaining working life of scheme members. Defined benefit schemes are funded, with the assets of the scheme held separately from those of the company in separate trustee administered funds. Differences between amounts charged to the profit and loss account and amounts funded are shown as either provisions or prepayments in the balance sheet.

Foreign currency translation

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction or, if hedged, at the forward contract rate. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are reported at the rates of exchange prevailing at date or, if appropriate, at the forward contract rate. All exchange differences are included in the profit and loss account.

2 Profit on ordinary activities before taxation

Profit on ordinary activities before taxation is stated after charging (crediting) depreciation of tangible fixed assets, and research and development costs.

3 Directors' Interests and remuneration

The directors have no interests and received no remuneration required to be disclosed under schedule 6 and 7 of the Companies Act 1985.

4 Tax on profit on ordinary activities

	The tax charges comprises:	2008 \$ '000	2007 \$ '000
	Corporation tax for the financial year	3,701	237,923
	Adjustment in respect of prior years	<u>•</u>	
		3,701	237,923
5	Dividends paid and proposed	2008 \$ '000	2007 \$ '000
	Dividends paid and processed 30 shares each at \$8,333 for 2006 and \$5,333 for 2005 respectively		
6	Tangible fixed assets (\$ '000)		
	As of 1 December 2007	31,132	
	Additions Revaluations Disposals / Retirement Transfers	6,279 (3,029) (4,504) 6,652	
	As of 30 November 2008	36,529	
	Depreciation		
	As of 1 December 2007	(16,328)	
	Charge for the year Disposals / Retirement	(150) <u>4,499</u>	
	As of 30 November 2008	(11,978)	
	Net Book Value		
	As of 1 December 2007	14,804	
	As of 30 November 2008	24,551	

7 Fixed assets investments

AlLLC is in control of less than 1% of ownership in Knoll subsidiary. Abbott Laboratories Incorporated is a 100% owner of Knoll Organization. Further information about AlLLC interest in Knoll can be obtained from Abbott Laboratories at 100 Abbott Park Road, Abbott Park, IL 60064-3500, United States.

8 Stocks

There is no material difference between the balance sheet value of stocks and the replacement cost.

9	Debtors	2008 \$ '000	2007 \$ '000
	Amounts falling due within one year:		
(A)	Trade debtors	1	1
(B)	Other debtors	20,805	(35,146)
(C)	Amounts due to group undertakings	781,813	1,016,717
(D)	Prepayments and accrued income	14,277	39,202
		816,896	1,020,775
	Amounts falling due after more than one year:		
(E)	Other debtors	3,288	7,620
(F)	Prepayments		
		3,288	7,620

10	Creditors: Amounts falling due within one year		
	•	2008 \$ '000	2007 \$ '000
	Other Creditors		
(A)	Trade Creditors	(5,722)	(6,032)
(B)	Amounts owed to group undertakings	(59,085)	(43,398)
(C)	US corporation tax	•	(222,653)
(D)	Other taxation and social security	(23)	(27)
(E)	Other creditors	(56,730)	(35,049)
		(121,560)	(307,160)
11	Called-up share capital		
		2008 \$ '000	2007 \$ '000
	250 ordinary shares of no par value authorized; 30 ordinary shares of no par value issued	53,424	53,424
12	Reconciliation of movements in shareholders' fun	ds	
		2008 \$ '000	2007 \$ '000
	Opening shareholders' funds (since 2002)	53,424	. 53,424
	Closing shareholders' funds	53,424	53,424

13 Profit and loss account

Front and loss account	2008 \$ '000	2007 \$ '000
Beginning of the year	729,684	298,040
Profit for the year after dividends paid	167	430,199
Other comprehensive income - translation	(13,793)	1,445
End of the year	716,058	729,684
	2008 \$ '000	2007 \$ '000
Profit for the year	167	430,199
Cash dividends	0	0
Profit for the year after dividends paid	167	430,199

14 Ultimate parent undertaking

The company is a subsidiary of Abbott Laboratories incorporated in the state of Illinois in the USA.

The accounts are consolidated with Abbott Laboratories.

The accounts of this group are available to the public from 100 Abbott Park Road, Abbott Park, IL 60064-3500, USA.